📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 16:35
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Medico Intercontinental Q1 Cons Net Loss Widens to Rs 4.04 Cr; Revenue Down 3% YoY to Rs 20.71 Cr
Medico Intercontinental reported consolidated revenue from operations of Rs 20.71 Cr for Q1 ended June 30, 2026, down 3.0% YoY from Rs 21.35 Cr and down 6.6% QoQ from Rs 22.19 Cr. Consolidated net loss expanded significantly to Rs 4.04 Cr compared to a net loss of Rs 2.49 Cr in Q1 FY26 and Rs 2.33 Cr in Q4 FY26. Net loss attributable to owners was Rs 1.45 Cr, translating to a diluted EPS of Rs -1.45. Standalone operations remained marginally profitable with a PAT of Rs 0.61 Cr on revenue of Rs 14.33 Cr.
Confidence: HIGH
What changedQ1 FY27 consolidated performance saw deepening net losses of Rs 4.04 Cr despite stable standalone operations.
Why it mattersPersistent consolidated losses continue to pressure net worth (Rs 47 Cr) in the face of elevated leverage (D/E of 1.43).
Consolidated Revenue: Rs 20.71 CrConsolidated Net Loss: Rs 4.04 CrStandalone PAT: Rs 60.76 LakhsConsolidated EPS: Rs -1.45Q1 Revenue vs TTM Revenue: ~24.7%
📅 Short termWidening quarterly losses and sluggish revenue growth are likely to weigh on sentiment.
📈 Long termSubstantial subsidiary drag needs operational turnaround to protect capital and reduce financial leverage.
⚠ Risk flags
- Widening consolidated losses
- High debt burden (Rs 67 Cr debt vs Rs 47 Cr net worth)
- Severe subsidiary underperformance relative to standalone
Key Highlights
Consolidated revenue from operations decreased 3.0% YoY to Rs 20.71 Cr (vs Rs 21.35 Cr in Q1 FY26)
Consolidated net loss widened to Rs 4.04 Cr compared to a loss of Rs 2.49 Cr in Q1 FY26 and Rs 2.33 Cr in Q4 FY26
Consolidated loss before tax expanded to Rs 3.68 Cr from Rs 2.04 Cr in the year-ago period
Standalone PAT stood at Rs 60.76 Lakhs on revenue of Rs 14.33 Cr, compared to Rs 55.60 Lakhs PAT in Q1 FY26
Annual General Meeting (AGM) scheduled for September 30, 2026, with cut-off date set to September 23, 2026
👀 What to Watch
Track the upcoming AGM on September 30, 2026, for management updates on subsidiary underperformance and cash burn containment.
Medico Intercontinental Q1 Cons. Loss Widens to ₹4.04 Cr; Revenue Down 3% YoY to ₹20.71 Cr
Medico Intercontinental reported consolidated revenue from operations of ₹20.71 Cr (₹2,071.15 lakhs) for the quarter ended June 30, 2026, down 3.0% YoY from ₹21.35 Cr in Q1 FY26. Consolidated net loss widened to ₹4.04 Cr compared to a loss of ₹2.49 Cr in Q1 FY26, burdened by finance costs of ₹1.91 Cr and operating expenses. On a standalone basis, the company posted a net profit of ₹0.61 Cr on revenue of ₹14.33 Cr. The company's 42nd Annual General Meeting is scheduled for September 30, 2026.
Confidence: HIGH
What changedQ1 FY27 results show widening consolidated net losses despite stable standalone profits, alongside the formal scheduling of the FY26 AGM.
Why it mattersThe company continues to face severe bottom-line drag from subsidiary operations and high finance costs, sustaining a multi-quarter consolidated loss trend.
Consolidated Revenue (Q1): ₹20.71 CrConsolidated Net Loss (Q1): ₹-4.04 CrConsolidated Finance Costs (Q1): ₹1.91 CrStandalone PAT (Q1): ₹0.61 CrAGM Date: 30 September, 2026
📅 Short termWeak consolidated numbers are likely to keep the stock under fundamental pressure over coming weeks.
📈 Long termWith D/E at 1.43x and continued consolidated losses, a turnaround hinges on rationalizing subsidiary cost structures and lowering debt levels.
⚠ Risk flags
- Persistent consolidated net losses
- Elevated finance costs and leverage (D/E 1.43)
- Significant subsidiary-level operating losses
Key Highlights
Consolidated revenue from operations decreased 3.0% YoY to ₹20.71 Cr vs ₹21.35 Cr in Q1 FY26
Consolidated net loss expanded to ₹4.04 Cr vs a loss of ₹2.49 Cr in the corresponding prior-year quarter
Standalone revenue stood at ₹14.33 Cr with PAT of ₹0.61 Cr and basic EPS of ₹0.61
Consolidated finance costs rose to ₹1.91 Cr against ₹1.36 Cr in Q1 FY26
Annual General Meeting set for September 30, 2026, with cut-off date on September 23, 2026
👀 What to Watch
Track whether subsidiaries can stem losses to stop dragging down consolidated profitability, and monitor debt reduction efforts to lower quarterly interest costs.
